Introduction
ANTIBODY-MEDIATED REJECTION
The presence of donor-specific antibody (DSA) and antibody-mediated rejections are poor prognostic factors for graft survival and a major cause of graft failure in kidney transplant (KT) patientsThe allograft survival rate was poorer in patients with de novo (dnDSA) than in those with preexisting DSA, although antibody-mediated rejection can occur in both patients with preexisting DSA and dnDSATherefore, it is important to actively control dnDSA and accompanying antibody-mediated rejection to improve kidney allograft outcomes. In previous studies, dnDSA reduction was identified only after intravenous immunoglobulin (IVIG) or rituximab use during desensitization